skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes

Original Research

(1782) Views  (650) Full article downloads

Authors: Yallapu MM, Ebeling MC, Chauhan N, Jaggi M, Chauhan SC


Video abstract presented by Subhash Chauhan
Views: 137

Published Date November 2011 Volume 2011:6 Pages 2779 - 2790
DOI: http://dx.doi.org/10.2147/IJN.S25534

Murali Mohan Yallapu1, Mara C Ebeling1, Neeraj Chauhan1,3, Meena Jaggi1-3, Subhash C Chauhan1-3
1Cancer Biology Research Center, Sanford Research, 2Department of Obstetrics and Gynecology, 3Basic Biomedical Science Division, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD

Background: Recent studies report curcumin nanoformulation(s) based on polylactic-co-glycolic acid (PLGA), ß-cyclodextrin, cellulose, nanogel, and dendrimers to have anticancer potential. However, no comparative data are currently available for the interaction of curcumin nanoformulations with blood proteins and erythrocytes. The objective of this study was to examine the interaction of curcumin nanoformulations with cancer cells, serum proteins, and human red blood cells, and to assess their potential application for in vivo preclinical and clinical studies.
Methods: The cellular uptake of curcumin nanoformulations was assessed by measuring curcumin levels in cancer cells using ultraviolet-visible spectrophotometry. Protein interaction studies were conducted using particle size analysis, zeta potential, and Western blot techniques. Curcumin nanoformulations were incubated with human red blood cells to evaluate their acute toxicity and hemocompatibility.
Results: Cellular uptake of curcumin nanoformulations by cancer cells demonstrated preferential uptake versus free curcumin. Particle sizes and zeta potentials of curucumin nanoformulations were varied after human serum albumin adsorption. A remarkable capacity of the dendrimer curcumin nanoformulation to bind to plasma protein was observed, while the other formulations showed minimal binding capacity. Dendrimer curcumin nanoformulations also showed higher toxicity to red blood cells compared with the other curcumin nanoformulations.
Conclusion: PLGA and nanogel curcumin nanoformulations appear to be very compatible with erythrocytes and have low serum protein binding characteristics, which suggests that they may be suitable for application in the treatment of malignancy. These findings advance our understanding of the characteristics of curcumin nanoformulations, a necessary component in harnessing and implementing improved in vivo effects of curcumin.

Keywords: nanoparticle, curcumin, chemotherapy, cellular uptake, protein binding, hemocompatibility




 

Other articles by Dr Subhash Chauhan



Readers of this article also read:

Biomimetic nanoparticles: preparation, characterization and biomedical applications
Bactericidal effect of iron oxide nanoparticles on Staphylococcus aureus
Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice
Formation of silver microbelt structures by laser irradiation of silver nanoparticles in ethanol
Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer
Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment
Preparation and evaluation of antimicrobial activity of nanosystems for the control of oral pathogens Streptococcus mutans and Candida albicans
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines
Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy
5-Fluorouracil-loaded poly(ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer